Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.91 million versus the consensus estimate of $7.05 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen